广济药业(000952) - 2019 Q3 - 季度财报

Financial Performance - Operating revenue for the reporting period was ¥189,852,096.42, down 8.37% compared to the same period last year[7]. - Net profit attributable to shareholders of the listed company was ¥41,407,137.11, a significant increase of 170.43% year-on-year[7]. - Basic earnings per share for the reporting period were ¥0.166, up 172.13% compared to the same period last year[7]. - Total operating revenue decreased to ¥189,852,096.42 from ¥207,203,376.98, representing a decline of approximately 8.5% year-over-year[39]. - Operating profit increased significantly to ¥48,415,666.05 compared to ¥18,487,505.08, marking an increase of approximately 161.5% year-over-year[40]. - Net profit rose to ¥40,311,145.48 from ¥14,370,475.25, reflecting an increase of around 180.5% year-over-year[40]. - Basic and diluted earnings per share improved to ¥0.166 from ¥0.061, indicating a growth of approximately 172.1% year-over-year[41]. - The total comprehensive income attributable to the parent company was ¥41,400,653.02, up from ¥15,311,394.84, reflecting an increase of about 170.5% year-over-year[41]. - Net profit for the current period is $102.02 million, a decline of 23.3% compared to $133.04 million in the previous period[48]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥1,774,050,853.41, an increase of 4.77% compared to the end of the previous year[7]. - Net assets attributable to shareholders of the listed company amounted to ¥977,627,540.28, reflecting an increase of 11.95% year-on-year[7]. - The total liabilities increased to CNY 790,926,157.68 from CNY 812,329,842.01, a decrease of approximately 2.5%[31]. - Current liabilities decreased to CNY 706,104,190.97 from CNY 727,994,089.62, a reduction of about 3.9%[31]. - Non-current liabilities remained relatively stable at CNY 84,821,966.71 compared to CNY 84,335,752.39, showing a slight increase of 0.6%[31]. - Owner's equity increased to CNY 983,124,695.73 from CNY 880,958,195.07, reflecting a growth of approximately 11.6%[32]. - Total assets increased to CNY 1,774,050,853.41, up from CNY 1,693,288,037.08, representing a growth of approximately 4.8% year-over-year[30]. - The total assets and liabilities combined reached CNY 1,671,096,397.78[68]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥84,848,912.16, a decrease of 50.82% compared to the same period last year[7]. - The net cash flow from financing activities decreased by 78.38% to -¥34,042,642.14, primarily due to an increase in short-term bank loans[15]. - Cash and cash equivalents increased by ¥17,563,847.59, reversing a negative change of -¥28,084,540.76 in the previous year[15]. - Operating cash inflow for the current period was CNY 565,922,570.99, a decrease of 7.9% from CNY 614,717,552.82 in the previous period[54]. - Net cash flow from operating activities was CNY 84,848,912.16, down 50.8% from CNY 172,542,663.70 in the previous period[55]. - Cash inflow from operating activities totaled CNY 630,453,012.21, an increase of 32.0% from CNY 477,520,458.53 in the previous period[57]. Expenses - Operating costs increased by ¥16,776,440.18 or 6.52%, totaling ¥274,125,773.25, primarily due to the recovery of production at a subsidiary[15]. - Sales expenses rose by 20.73% to ¥28,511,071.20, attributed to increased packaging and transportation costs related to higher sales volume of the main product[15]. - Management expenses increased by 30.41% to ¥86,789,046.95, mainly due to increased losses from the suspension of GMP renovation at the parent company's infusion workshop[15]. - Research and development expenses decreased to ¥14,306,590.91 from ¥17,996,309.20, a reduction of about 20.0% year-over-year[39]. - Tax expenses increased to ¥7,856,830.58 from ¥3,111,529.52, an increase of approximately 152.5% year-over-year[40]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 36,774[11]. - The largest shareholder, Hubei Yangtze River Industry Investment Group Co., Ltd., held 16.57% of the shares, totaling 41,710,801 shares[11]. Government Support - The company received government subsidies amounting to ¥33,235,108.59 during the reporting period[8]. Inventory and Receivables - The company reported a significant increase in inventory, which rose to ¥169,514,942.10 from ¥98,486,134.87 year-on-year[29]. - Accounts receivable decreased to ¥103,593,913.02 from ¥113,176,456.10, indicating improved collection efforts[29]. - Accounts receivable increased to CNY 20,031,969.04 from CNY 34,463,843.69, indicating a decrease of approximately 41.8%[34]. Financial Reporting Changes - The company has not undergone an audit for the third quarter report[69]. - The report reflects adjustments in financial reporting formats without impacting net profit or shareholder equity[68]. - The company has implemented new financial instrument and leasing standards, affecting the presentation of receivables and payables[69].